LPI (LP Information)' newest research report, the ﾓCell-Free Fetal DNA Testing Industry Forecastﾔ looks at past sales and reviews total world Cell-Free Fetal DNA Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Cell-Free Fetal DNA Testing sales for 2023 through 2029. With Cell-Free Fetal DNA Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell-Free Fetal DNA Testing industry. This Insight Report provides a comprehensive analysis of the global Cell-Free Fetal DNA Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cell-Free Fetal DNA Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firmsﾒ unique position in an accelerating global Cell-Free Fetal DNA Testing market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell-Free Fetal DNA Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell-Free Fetal DNA Testing. The global Cell-Free Fetal DNA Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029. United States market for Cell-Free Fetal DNA Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. China market for Cell-Free Fetal DNA Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Europe market for Cell-Free Fetal DNA Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Global key Cell-Free Fetal DNA Testing players cover Sequenom Laboratories, Illumina, Inc., Ariosa Diagnostics, Arup Laboratories, The Fetal Medicine Centre and Apollo Path labs, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022. This report presents a comprehensive overview, market shares, and growth opportunities of Cell-Free Fetal DNA Testing market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type Abnormal Chromosome Number Detection Gender Testing Paternally Inherited Disorder Detection Paternity testing Others Segmentation by application Hospital Clinic Center This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Sequenom Laboratories Illumina, Inc. Ariosa Diagnostics Arup Laboratories The Fetal Medicine Centre Apollo Path labs
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Cell-Free Fetal DNA Testing Market Size 2018-2029 2
